Alirocumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Alirocumab comprises 262 peer-reviewed publications across 15 journals, 28 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Hypercholesterolemia, Intracranial Arteriosclerosis, Atherosclerosis, and Dyslipidemias. Most recent publication: Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease., Atheroscler Plus, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C, Krane V, März W, et al. · N Engl J Med · 2005
    PubMed: PMID 16034009 · NCT03480568 · Hypercholesterolemia
  2. Alirocumab and plaque volume, calf muscle blood flow, and walking performance in peripheral artery disease: A randomized clinical trial.
    Rrapo-Kaso E, Loffler AI, Petroni GR, et al. · Vasc Med · 2023
    PubMed: PMID 37093712 · NCT02959047 · Peripheral Arterial Disease
  3. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
    Roth EM, McKenney JM, Hanotin C, et al. · N Engl J Med · 2012
    PubMed: PMID 23113833 · NCT01288469 · Hypercholesterolemia
  4. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG, Farnier M, Krempf M, et al. · N Engl J Med · 2015
    PubMed: PMID 25773378 · NCT01507831 · Hypercholesterolemia
  5. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
    Fellström BC, Jardine AG, Schmieder RE, et al. · N Engl J Med · 2009
    PubMed: PMID 19332456 · NCT03480568 · Hypercholesterolemia
  6. Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.
    Fearon WF, Terada K, Takahashi K, et al. · Circulation · 2025
    PubMed: PMID 41212178 · NCT03537742 (CAVIAR) · Vascular Diseases
  7. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    Everett BM, Smith RJ, Hiatt WR, et al. · N Engl J Med · 2015
    PubMed: PMID 26444323 · NCT03480568 · Hypercholesterolemia
  8. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    Baigent C, Landray MJ, Reith C, et al. · Lancet · 2011
    PubMed: PMID 21663949 · NCT03480568 · Hypercholesterolemia

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01507831HypercholesterolemiaPercentage of Participants Who Experienced Adverse Events (AEs)
Up to 10 weeks after last study drug administration (maximum of 86 weeks)
Alirocumab 150 mg Q2W81.0 percentage of participants
Alirocumab 150 mg Q2W0.5 percentage of participants
Alirocumab 150 mg Q2W18.7 percentage of participants
Alirocumab 150 mg Q2W7.2 percentage of participants
Placebo Q2W1.3 percentage of participants
Placebo Q2W19.5 percentage of participants
Placebo Q2W82.5 percentage of participants
Placebo Q2W5.8 percentage of participants
NCT01617655HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis
From Baseline to Week 52
Alirocumab 150 mg Q2W-45.7 percent change (±3.5 Standard Error)
Placebo Q2W-6.6 percent change (±4.9 Standard Error)
NCT01623115
ODYSSEY FH I
HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
From Baseline to Week 52
Alirocumab 75 mg/Up to 150 mg Q2W-48.8 percent change (±1.6 Standard Error)
Placebo9.1 percent change (±2.2 Standard Error)
NCT01644175HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
From Baseline to Week 52
Alirocumab 75/150 mg Q2W-48.2 percent change (±1.9 Standard Error)
Placebo Q2W-2.3 percent change (±2.7 Standard Error)
NCT01644188HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis
From Baseline to Week 52
Alirocumab 75 /up to 150 mg Q2W-50.6 percent change (±1.4 Standard Error)
Ezetimibe 10 mg-20.7 percent change (±1.9 Standard Error)
NCT01644474
ODYSSEY MONO
HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
From Baseline to Week 24
Alirocumab 75/Up to 150 mg Q2W-47.2 percent change (±3.0 Standard Error)
Ezetimibe 10 mg-15.6 percent change (±3.1 Standard Error)
NCT01663402AtherosclerosisTime to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study
From randomization up to 64 months
Alirocumab 75 mg Q2W/Up to 150 mg Q2W9.5 percentage of participants
Placebo11.1 percentage of participants
NCT01709500
ODYSSEY FH II
—Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis
From Baseline to Week 52
Alirocumab 75 mg/up to 150 mg-48.7 percent change (±1.9 Standard Error)
Placebo2.8 percent change (±2.8 Standard Error)
NCT01709513HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis
From Baseline to Week 24
Alirocumab 75 mg/ up to 150 mg-45.0 percent change (±2.2 Standard Error)
Ezetimibe-14.6 percent change (±2.2 Standard Error)
NCT01730040HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis
From Baseline to Week 24
Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg-44.1 percent change (±4.5 Standard Error)
Alirocumab 75 mg/up to 150 mg + Atorvastatin 40 mg-54 percent change (±4.3 Standard Error)
Atorvastatin 40 mg-5 percent change (±4.6 Standard Error)
Atorvastatin 80 mg-4.8 percent change (±4.2 Standard Error)
Ezetimibe 10 mg + Atorvastatin 20 mg-20.5 percent change (±4.7 Standard Error)
Ezetimibe 10 mg + Atorvastatin 40 mg-22.6 percent change (±4.3 Standard Error)
Rosuvastatin 40 mg-21.4 percent change (±4.2 Standard Error)
NCT01730053HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
From Baseline to Week 24
Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg-50.6 percent change (±4.2 Standard Error)
Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg-36.3 percent change (±7.1 Standard Error)
Ezetimibe 10 mg + Rosuvastatin 10 mg-14.4 percent change (±4.4 Standard Error)
Ezetimibe 10 mg + Rosuvastatin 20 mg-11.0 percent change (±7.2 Standard Error)
Rosuvastatin 20 mg-16.3 percent change (±4.1 Standard Error)
Rosuvastatin 40 mg-15.9 percent change (±7.1 Standard Error)
NCT01926782HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis
From Baseline to Week 24
Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin-56.9 percent change (±1.8 Standard Error)
Alirocumab 300 mg Q4W/Up 150 mg Q2W Without Concomitant Statin-52.7 percent change (±1.9 Standard Error)
Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin-54 percent change (±3.6 Standard Error)
Alirocumab 75 mg Q2W/Up 150 mg Q2W Without Concomitant Statin-50.2 percent change (±3.7 Standard Error)
Placebo Q2W Without Concomitant Statin-0.3 percent change (±2.7 Standard Error)
Placebo Q2W Without Concomitant Statin-1.6 percent change (±2.6 Standard Error)
NCT01926782HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)
From Baseline to Week 24
Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin-65.8 percent change (±1.4 Standard Error)
Alirocumab 300 mg Q4W/Up 150 mg Q2W With Concomitant Statin-58.8 percent change (±1.6 Standard Error)
Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin-57.9 percent change (±2.8 Standard Error)
Alirocumab 75 mg Q2W/Up 150 mg Q2W With Concomitant Statin-51.6 percent change (±3.3 Standard Error)
Placebo Q2W With Concomitant Statin-0.1 percent change (±2.3 Standard Error)
Placebo Q2W With Concomitant Statin0.8 percent change (±2.0 Standard Error)
NCT01954394
ODYSSEY OLE
HypercholesterolemiaPercentage of Participants Who Experienced Adverse Events (AEs)
Up to 10 weeks after last study drug administration (maximum of 176 weeks)
Alirocumab to Alirocumab 75 or 150 mg Q2W3.5 percentage of participants
Alirocumab to Alirocumab 75 or 150 mg Q2W87.3 percentage of participants
Alirocumab to Alirocumab 75 or 150 mg Q2W22.0 percentage of participants
Alirocumab: All Participants21.5 percentage of participants
Alirocumab: All Participants86.2 percentage of participants
Alirocumab: All Participants3.4 percentage of participants
Placebo to Alirocumab 75 or 150 mg Q2W3.0 percentage of participants
Placebo to Alirocumab 75 or 150 mg Q2W83.9 percentage of participants
Placebo to Alirocumab 75 or 150 mg Q2W20.6 percentage of participants
NCT02023879HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)
From Baseline to Week 24
Alirocumab 150 mg Q4W/Up to 150 mg Q2W-51.7 percent change (±2.3 Standard Error)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)-53.5 percent change (±1.6 Standard Error)
Placebo Q2W4.7 percent change (±2.3 Standard Error)
NCT02107898HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)
From Baseline to Week 24
Alirocumab 75 mg/Up to 150 mg Q2W-62.5 percent change (±1.3 Standard Error)
Placebo Q2W1.6 percent change (±1.8 Standard Error)
NCT02289963HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
From Baseline to Week 24
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-57.1 percent change (±3.0 Standard Error)
Placebo Q2W6.3 percent change (±2.9 Standard Error)
NCT02326220
ODYSSEY ESCAPE
—Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18
Week 7 to Week 18 (before start of open-label treatment)
Alirocumab 150 mg Q2W (Double Blind Period)0.128 Treatments (±0.242 Standard Deviation)
Placebo Q2W (Double Blind Period)0.806 Treatments (±0.191 Standard Deviation)
NCT02476006HypercholesterolemiaPercentage of Participants With Treatment Emergent Adverse Events (TEAEs)
From first injection of investigational medicinal product (IMP) up to 2 weeks after last dose of study drug (Week 120)
Alirocumab16.2 percentage of participants
Alirocumab0.2 percentage of participants
Alirocumab4.5 percentage of participants
Alirocumab71.6 percentage of participants
NCT02584504
ODYSSEY-NIPPON
HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis
From Baseline to Week 12
Alirocumab 150 mg Q2W-70.1 percent change (±2.3 Standard Error)
Alirocumab 150 mg Q4W-43.8 percent change (±2.2 Standard Error)
Placebo Q2W-4.3 percent change (±2.2 Standard Error)
NCT02585778HypercholesterolemiaPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis
From Baseline to Week 24
Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T1DM Participants-51.8 percent change (±3.7 Standard Error)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W: T2DM Participants-48.2 percent change (±1.6 Standard Error)
Placebo Q2W: T1DM Participants-3.9 percent change (±5.3 Standard Error)
Placebo Q2W: T2DM Participants0.8 percent change (±2.2 Standard Error)
NCT02585778HypercholesterolemiaPercentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)
From Baseline up to 10 weeks after last study drug administration (maximum of 32 weeks)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W0 percentage of participants
Alirocumab 75 mg Q2W/Up to 150 mg Q2W64.5 percentage of participants
Alirocumab 75 mg Q2W/Up to 150 mg Q2W9.0 percentage of participants
Alirocumab 75 mg Q2W/Up to 150 mg Q2W4.9 percentage of participants
Placebo Q2W2.4 percentage of participants
Placebo Q2W64.1 percentage of participants
Placebo Q2W9.4 percentage of participants
Placebo Q2W0.6 percentage of participants
NCT02715726
ODYSSEY EAST
HypercholesterolemiaPercent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis
From Baseline to Week 24
Alirocumab 75 mg Q2W/up to 150 mg Q2W-56.0 percent change (±1.5 Standard Error)
Ezetimibe 10 mg-20.3 percent change (±2.0 Standard Error)
NCT03156621
ODYSSEY HoFH
Homozygous Familial HypercholesterolemiaPercent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand)
Baseline to Week 12
Alirocumab 150 mg SC Q2W-26.9 Percentage of change (±4.6 Standard Error)
Placebo in DBTP8.6 Percentage of change (±6.3 Standard Error)
NCT03415178HypercholesterolemiaPercentage of SYDNEY-Associated Product Technical Complaints (PTCs) (by Type) at the Unsupervised Injections: Single-Arm Period
From Week 4 up to Week 12
New Auto-Injector Device (SYDNEY)0.5 percentage of PTCs
New Auto-Injector Device (SYDNEY)0 percentage of PTCs
New Auto-Injector Device (SYDNEY)0 percentage of PTCs
NCT03415178HypercholesterolemiaPercentage of SYDNEY-Associated Product Technical Complaints (PTCs) (Overall) at the Unsupervised Injections: Single-Arm Period
From Week 4 up to Week 12
New Auto-Injector Device (SYDNEY)0.5 percentage of PTCs
NCT03510715HypercholesterolemiaPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis
Baseline to Week 12
Alirocumab-4.1 percent change (±9.0 Standard Error)
NCT03510884HypercholesterolemiaDB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand
Baseline, Week 24
DB Period: Alirocumab Q2W-33.6 percent change (±3.4 Standard Error)
DB Period: Alirocumab Q4W-38.2 percent change (±4.0 Standard Error)
DB Period: Placebo Q2W9.7 percent change (±4.3 Standard Error)
DB Period: Placebo Q4W-4.4 percent change (±3.7 Standard Error)

Publications by year

1988–2026: 262 publications.

1988
1
1995
1
1996
3
1997
2
1999
2
2000
2
2001
1
2003
1
2004
3
2005
3
2006
4
2007
4
2008
3
2009
7
2010
3
2011
9
2012
10
2013
6
2014
16
2015
24
2016
17
2017
19
2018
16
2019
10
2020
30
2021
21
2022
12
2023
9
2024
11
2025
8
2026
4

Publications by indication

Hypercholesterolemia (67)

  • Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
    JAMA Pediatr · 2024 · PMID 38315470 · NCT03510884
  • Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial.
    EuroIntervention · 2022 · PMID 36349701 · NCT03718286
  • Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen).
    Kidney Med · 2022 · PMID 35801187 · NCT03480568
  • A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort.
    Nutr Metab Cardiovasc Dis · 2022 · PMID 36064689 · NCT02476006
  • Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study.
    Arterioscler Thromb Vasc Biol · 2022 · PMID 36325897 · NCT03510715

Intracranial Arteriosclerosis (53)

  • Design of the "EAST" strategy in patients with asymptomatic intracranial atherosclerotic stenosis.
    Clin Neurol Neurosurg · 2024 · PMID 39182330 · NCT06080256
  • PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging.
    BMJ Open · 2022 · PMID 35487727 · NCT05001984
  • High-resolution MRI of intracranial large artery diseases: how to use it in clinical practice?
    Stroke Vasc Neurol · 2021 · PMID 31338221 · NCT05001984
  • Magnetic Resonance Imaging Detection of Intraplaque Hemorrhage.
    Magn Reson Insights · 2020 · PMID 28469441 · NCT03507374
  • Is the future of symptomatic intracranial atherosclerotic stenosis management promising?
    J Neurol Neurosurg Psychiatry · 2020 · PMID 31919104 · NCT05001984

Atherosclerosis (35)

  • Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.
    Circulation · 2025 · PMID 41321238 · NCT01663402
  • Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES.
    Circulation · 2025 · PMID 40193536 · NCT01663402
  • Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.
    Arterioscler Thromb Vasc Biol · 2025 · PMID 40995631 · NCT01663402
  • Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.
    J Am Heart Assoc · 2025 · PMID 40847481 · NCT01663402
  • Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES.
    Am J Prev Cardiol · 2025 · PMID 39687787 · NCT01663402

Dyslipidemias (30)

  • Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease.
    Atheroscler Plus · 2026 · PMID 42007426 · NCT04613167
  • Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial.
    Am Heart J · 2026 · PMID 41771366 · NCT03207945
  • Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial.
    Eur J Med Res · 2025 · PMID 40001082 · NCT04613167
  • Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients.
    Eur J Pharmacol · 2024 · PMID 38070635 · NCT04613167
  • Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.
    Cardiovasc Ultrasound · 2023 · PMID 37580777 · NCT04613167

Plaque, Atherosclerotic (19)

  • Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins.
    Circ Genom Precis Med · 2026 · PMID 41664920 · NCT03067844
  • Intake of high-intensity statin after acute myocardial infarction assessed by direct drug concentration measurement: association with LDL-C response and coronary plaque modifications in the PACMAN-AMI trial.
    Eur J Prev Cardiol · 2025 · PMID 40796144 · NCT03067844
  • Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.
    Atherosclerosis · 2024 · PMID 38513436 · NCT03067844
  • Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab.
    Circ Cardiovasc Imaging · 2024 · PMID 39561225 · NCT03067844
  • Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial.
    JAMA Cardiol · 2024 · PMID 39221516 · NCT03067844

Sepsis (18)

  • Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.
    J Am Heart Assoc · 2018 · PMID 29223954 · NCT03634293
  • Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.
    Lipids Health Dis · 2018 · PMID 28738813 · NCT03634293
  • Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.
    J Lipid Res · 2018 · PMID 28600283 · NCT03634293
  • Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
    Cardiovasc Res · 2017 · PMID 27496869 · NCT03634293
  • Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
    Br J Clin Pharmacol · 2017 · PMID 27478094 · NCT03634293

Publications by journal

Trial-results highlights

Clinical trials investigated Alirocumab for hypercholesterolemia. In NCT01617655, the Alirocumab 150 mg Q2W arm showed a -45.7 percent change from baseline in calculated LDL-C at week 24, while the placebo Q2W arm showed a -6.6 percent change. Similarly, in NCT01623115 (ODYSSEY FH I), the Alirocumab 75 mg/Up to 150 mg Q2W arm had a -48.8 percent change, compared to a 9.1 percent change in the placebo arm. NCT01644175 reported a -48.2 percent change for the Alirocumab 75/150 mg Q2W arm and a -2.3 percent change for the placebo Q2W arm. In NCT01709500 (ODYSSEY FH II), the Alirocumab 75 mg/up to 150 mg arm showed a -48.7 percent change, versus a 2.8 percent change in the placebo arm. When compared to ezetimibe, the Alirocumab 75 /up to 150 mg Q2W arm in NCT01644188 showed a -50.6 percent change in LDL-C, while the ezetimibe 10 mg arm showed a -20.7 percent change. In NCT01644474 (ODYSSEY MONO), the Alirocumab 75/Up to 150 mg Q2W arm demonstrated a -47.2 percent change, and the ezetimibe 10 mg arm showed a -15.6 percent change.

Regarding adverse events, data from NCT01507831 showed that 81.0 percentage of participants in the Alirocumab 150 mg Q2W arm experienced adverse events. Other reported percentages for the Alirocumab 150 mg Q2W arm included 0.5 percentage, 18.7 percentage, and 7.2 percentage of participants. For the placebo Q2W arm in the same study, 1.3 percentage and 19.5 percentage of participants experienced adverse events. In a study focused on atherosclerosis, NCT01663402, the percentage of participants who experienced a major adverse cardiovascular event (MACE) was 9.5 percentage in the Alirocumab 75 mg Q2W/Up to 150 mg Q2W arm, compared to 11.1 percentage in the placebo arm.

All values are sourced from primary registry reporting; individual publications should be consulted for clinical decision-making.

All Alirocumab publications (262)

2026 (4 papers)

  1. Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease.
    Ugovšek S, Rehberger Likozar A, Levstek T, et al. · Atheroscler Plus · 2026 · Derived
    PubMed: PMID 42007426 · NCT04613167 (GEBI) · Dyslipidemias
  2. Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins.
    Schmidt LE, Burnap SA, Singh B, et al. · Circ Genom Precis Med · 2026 · Derived
    PubMed: PMID 41664920 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  3. Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.
    Oduah EI, Zhang T, Jung SH, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 41940540 · NCT05553834 · Carcinoma, Non-Small-Cell Lung
  4. Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial.
    Durstenfeld MS, Levkova-Clark M, Li D, et al. · Am Heart J · 2026 · Derived
    PubMed: PMID 41771366 · NCT03207945 (EPIC-HIV) · Dyslipidemias

2025 (8 papers)

  1. Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.
    Fearon WF, Terada K, Takahashi K, et al. · Circulation · 2025 · Trial result
    PubMed: PMID 41212178 · NCT03537742 (CAVIAR) · Vascular Diseases
  2. Intake of high-intensity statin after acute myocardial infarction assessed by direct drug concentration measurement: association with LDL-C response and coronary plaque modifications in the PACMAN-AMI trial.
    van der Velpen V, Häner JD, Kakizaki R, et al. · Eur J Prev Cardiol · 2025 · Derived
    PubMed: PMID 40796144 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  3. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.
    Tsimikas S, Szarek M, Cobbaert CM, et al. · Circulation · 2025 · Derived
    PubMed: PMID 41321238 · NCT01663402 · Atherosclerosis
  4. Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES.
    Steg PG, Szarek M, Jukema JW, et al. · Circulation · 2025 · Derived
    PubMed: PMID 40193536 · NCT01663402 · Atherosclerosis
  5. Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.
    Reijnders E, Bossuyt PM, Jukema JW, et al. · Arterioscler Thromb Vasc Biol · 2025 · Derived
    PubMed: PMID 40995631 · NCT01663402 · Atherosclerosis
  6. Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial.
    Rehberger Likozar A, Levstek T, Karun T, et al. · Eur J Med Res · 2025 · Derived
    PubMed: PMID 40001082 · NCT04613167 (GEBI) · Dyslipidemias
  7. Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.
    Geba GP, Mohammadi KA, Damask A, et al. · J Am Heart Assoc · 2025 · Derived
    PubMed: PMID 40847481 · NCT01663402 · Atherosclerosis
  8. Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES.
    Geba GP, Chen R, Talapatra K, et al. · Am J Prev Cardiol · 2025 · Derived
    PubMed: PMID 39687787 · NCT01663402 · Atherosclerosis

2024 (11 papers)

  1. Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.
    Zahger D, Schwartz GG, Du W, et al. · J Am Coll Cardiol · 2024 · Derived
    PubMed: PMID 39232634 · NCT01663402 · Atherosclerosis
  2. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
    Szarek M, Reijnders E, Jukema JW, et al. · Circulation · 2024 · Derived
    PubMed: PMID 37632469 · NCT01663402 · Atherosclerosis
  3. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
    Schwartz GG, Szarek M, Bhatt DL, et al. · Eur Heart J · 2024 · Derived
    PubMed: PMID 36879424 · NCT01663402 · Atherosclerosis
  4. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
    Santos RD, Wiegman A, Caprio S, et al. · JAMA Pediatr · 2024 · Derived
    PubMed: PMID 38315470 · NCT03510884 · Hypercholesterolemia
  5. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.
    Rexhaj E, Bär S, Soria R, et al. · Atherosclerosis · 2024 · Derived
    PubMed: PMID 38513436 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  6. Quality Assurance for Multiplex Quantitative Clinical Chemistry Proteomics in Large Clinical Trials.
    Reijnders E, Romijn FPHTM, Arslan F, et al. · J Appl Lab Med · 2024 · Derived
    PubMed: PMID 39239905 · NCT01663402 · Atherosclerosis
  7. Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients.
    Rehberger Likozar A, Ugovšek S, Šebeštjen M, et al. · Eur J Pharmacol · 2024 · Derived
    PubMed: PMID 38070635 · NCT04613167 (GEBI) · Dyslipidemias
  8. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study.
    Pérez de Isla L, Díaz-Díaz JL, Romero MJ, et al. · Circ Cardiovasc Imaging · 2024 · Derived
    PubMed: PMID 38205656 · NCT05465278 (ARCHITECT) · Hyperlipoproteinemia Type II
  9. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab.
    Koskinas KC, Häner J, Ueki Y, et al. · Circ Cardiovasc Imaging · 2024 · Derived
    PubMed: PMID 39561225 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  10. Design of the "EAST" strategy in patients with asymptomatic intracranial atherosclerotic stenosis.
    Chen X, Dai J, Nie P, et al. · Clin Neurol Neurosurg · 2024 · Derived
    PubMed: PMID 39182330 · NCT06080256 (EAST-aICAS) · Intracranial Arteriosclerosis
  11. Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial.
    Biccirè FG, Kakizaki R, Koskinas KC, et al. · JAMA Cardiol · 2024 · Derived
    PubMed: PMID 39221516 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic

2023 (9 papers)

  1. Alirocumab and plaque volume, calf muscle blood flow, and walking performance in peripheral artery disease: A randomized clinical trial.
    Rrapo-Kaso E, Loffler AI, Petroni GR, et al. · Vasc Med · 2023 · Trial result
    PubMed: PMID 37093712 · NCT02959047 · Peripheral Arterial Disease
  2. Effect of alirocumab on cataracts in patients with acute coronary syndromes.
    Suc G, Schwartz GG, Goodman SG, et al. · BMC Ophthalmol · 2023 · Derived
    PubMed: PMID 37328736 · NCT01663402 · Atherosclerosis
  3. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Pérez de Isla L, Díaz-Díaz JL, Romero MJ, et al. · Circulation · 2023 · Derived
    PubMed: PMID 37009731 · NCT05465278 (ARCHITECT) · Hyperlipoproteinemia Type II
  4. Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.
    Likozar AR, Šebeštjen M · Cardiovasc Ultrasound · 2023 · Derived
    PubMed: PMID 37580777 · NCT04613167 (GEBI) · Dyslipidemias
  5. Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis.
    Lawler PR, Manvelian G, Coppi A, et al. · Crit Care Explor · 2023 · Derived
    PubMed: PMID 37954898 · NCT01663402 · Atherosclerosis
  6. Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.
    Goodman SG, Steg PG, Poulouin Y, et al. · J Am Heart Assoc · 2023 · Derived
    PubMed: PMID 37702079 · NCT01663402 · Atherosclerosis
  7. Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy.
    Biccirè FG, Häner J, Losdat S, et al. · J Am Coll Cardiol · 2023 · Derived
    PubMed: PMID 37640248 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  8. Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial.
    Bär S, Kavaliauskaite R, Otsuka T, et al. · EuroIntervention · 2023 · Derived
    PubMed: PMID 37341586 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  9. Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial.
    Hong KS, Bang OY, Park JH, et al. · J Stroke · 2023 · Background
    PubMed: PMID 37032475 · NCT06083961 · Ischemic Stroke

2022 (12 papers)

  1. Impact of early PCSK9 inhibitor treatment on heart after percutaneous coronary intervention in patients with STEMI: Design and rationale of the PERFECT II trial.
    Xia J, Wang X, Zhou J, et al. · Front Cardiovasc Med · 2022 · Derived
    PubMed: PMID 36211588 · NCT05292404
  2. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.
    Räber L, Ueki Y, Otsuka T, et al. · JAMA · 2022 · Derived
    PubMed: PMID 35368058 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  3. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.
    Ostadal P, Steg PG, Poulouin Y, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 35378068 · NCT01663402 · Atherosclerosis
  4. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial.
    Mehta SR, Pare G, Lonn EM, et al. · EuroIntervention · 2022 · Derived
    PubMed: PMID 36349701 · NCT03718286 (EPIC STEMI) · Hypercholesterolemia
  5. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial.
    Lopes RD, Guimarães PO, Schwartz GG, et al. · Am J Med · 2022 · Derived
    PubMed: PMID 35296402 · NCT01663402 · Atherosclerosis
  6. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
    Landmesser U, McGinniss J, Steg PG, et al. · Eur J Prev Cardiol · 2022 · Derived
    PubMed: PMID 35708715 · NCT01663402 · Atherosclerosis
  7. PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging.
    Huang YC, Chang CH, Tsai YH, et al. · BMJ Open · 2022 · Derived
    PubMed: PMID 35487727 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  8. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
    Hagström E, Steg PG, Szarek M, et al. · Circulation · 2022 · Derived
    PubMed: PMID 35770629 · NCT01663402 · Atherosclerosis
  9. Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen).
    East C, Bass K, Mehta A, et al. · Kidney Med · 2022 · Derived
    PubMed: PMID 35801187 · NCT03480568 · Hypercholesterolemia
  10. Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES.
    Chiang CE, Schwartz GG, Elbez Y, et al. · Can J Cardiol · 2022 · Derived
    PubMed: PMID 35644332 · NCT01663402 · Atherosclerosis
  11. A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort.
    Cefalù AB, Garbelotto R, Mombelli G, et al. · Nutr Metab Cardiovasc Dis · 2022 · Derived
    PubMed: PMID 36064689 · NCT02476006 · Hypercholesterolemia
  12. Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study.
    Bruckert E, Caprio S, Wiegman A, et al. · Arterioscler Thromb Vasc Biol · 2022 · Derived
    PubMed: PMID 36325897 · NCT03510715 · Hypercholesterolemia

2021 (21 papers)

  1. Chapter 2: Pharmacological cholesterol-lowering treatment in adults.
    Kidney Int Suppl (2011) · 2021 · Trial result
    PubMed: PMID 25019001 · NCT03480568 · Hypercholesterolemia
  2. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
    Zanchin C, Koskinas KC, Ueki Y, et al. · Am Heart J · 2021 · Derived
    PubMed: PMID 33951415 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  3. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
    Szarek M, Bittner VA, Aylward P, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 33051646 · NCT01663402 · Atherosclerosis
  4. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
    Schwartz GG, Szarek M, Bittner VA, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 34325831 · NCT01663402 · Atherosclerosis
  5. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment.
    Schwartz GG, Szarek M, Bittner VA, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 33722880 · NCT01663402 · Atherosclerosis
  6. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG, Steg PG, Szarek M, et al. · Circulation · 2021 · Derived
    PubMed: PMID 32223446 · NCT01663402 · Atherosclerosis
  7. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
    Schwartz GG, Gabriel Steg P, Bhatt DL, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33438437 · NCT01663402 · Atherosclerosis
  8. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.
    Roth EM, Kastelein JJP, Cannon CP, et al. · J Clin Lipidol · 2021 · Derived
    PubMed: PMID 32928709 · NCT01926782 · Hypercholesterolemia
  9. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.
    Moriarty PM, Thompson PD, Cannon CP, et al. · J Clin Lipidol · 2021 · Derived
    PubMed: PMID 32192644 · NCT01709513 · Hypercholesterolemia
  10. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies.
    Mahmood T, Minnier J, Ito MK, et al. · Eur J Prev Cardiol · 2021 · Derived
    PubMed: PMID 34298554 · NCT01730040 · Hypercholesterolemia
  11. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study.
    Li H, Wei Y, Yang Z, et al. · Am J Cardiovasc Drugs · 2021 · Derived
    PubMed: PMID 32080823 · NCT02979015 · Hypercholesterolemia
  12. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand.
    Han Y, Chen J, Chopra VK, et al. · J Clin Lipidol · 2021 · Derived
    PubMed: PMID 31882376 · NCT02715726 (ODYSSEY EAST) · Hypercholesterolemia
  13. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
    Diaz R, Li QH, Bhatt DL, et al. · Eur J Prev Cardiol · 2021 · Derived
    PubMed: PMID 33755145 · NCT01663402 · Atherosclerosis
  14. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.
    Daniels S, Caprio S, Chaudhari U, et al. · J Clin Lipidol · 2021 · Derived
    PubMed: PMID 32331936 · NCT02890992 (ODYSSEY KIDS) · Hypercholesterolemia
  15. Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study.
    Cacciottolo PJ, Kostapanos MS, Hernan Sancho E, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 33849844 · NCT03355027 (INTENSITY-HIGH) · Atherosclerosis
  16. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
    Blom DJ, Harada-Shiba M, Rubba P, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 32646561 · NCT03156621 (ODYSSEY HoFH) · Homozygous Familial Hypercholesterolemia
  17. High-resolution MRI of intracranial large artery diseases: how to use it in clinical practice?
    Xu W · Stroke Vasc Neurol · 2021 · Background
    PubMed: PMID 31338221 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  18. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.
    Rehberger Likozar A, Zavrtanik M, Šebeštjen M, et al. · Ann Med · 2021 · Background
    PubMed: PMID 32453609 · NCT04613167 (GEBI) · Dyslipidemias
  19. LDL-C: lower is better for longer-even at low risk.
    Penson PE, Pirro M, Banach M, et al. · BMC Med · 2021 · Background
    PubMed: PMID 33032586 · NCT06083961 · Ischemic Stroke
  20. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
    Mach F, Baigent C, Catapano AL, et al. · Eur Heart J · 2021 · Background
    PubMed: PMID 31504418 · NCT06083961 · Ischemic Stroke
  21. Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial.
    Leucker TM, Blaha MJ, Jones SR, et al. · Circulation · 2021 · Background
    PubMed: PMID 32718248 · NCT06083961 · Ischemic Stroke

2020 (30 papers)

  1. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
    Teramoto T, Kiyosue A, Ishigaki Y, et al. · J Cardiol · 2020 · Derived
    PubMed: PMID 30509509 · NCT02584504 (ODYSSEY-NIPPON) · Hypercholesterolemia
  2. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.
    Szarek M, Steg PG, DiCenso D, et al. · Circ Cardiovasc Qual Outcomes · 2020 · Derived
    PubMed: PMID 31707826 · NCT01663402 · Atherosclerosis
  3. Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
    Steg PG, Szarek M, Bhatt DL, et al. · Circulation · 2020 · Derived
    PubMed: PMID 31117810 · NCT01663402 · Atherosclerosis
  4. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF, Carter JL, Pearce LS, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 33078867 · NCT02585778 · Hypercholesterolemia
  5. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT, Li QH, Bhatt DL, et al. · Circulation · 2020 · Derived
    PubMed: PMID 31475572 · NCT01663402 · Atherosclerosis
  6. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK, Del Prato S, Müller-Wieland D, et al. · Cardiovasc Diabetol · 2020 · Derived
    PubMed: PMID 31706300 · NCT02642159 · Dyslipidemias
  7. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
    Ray KK, Colhoun HM, Szarek M, et al. · Lancet Diabetes Endocrinol · 2020 · Derived
    PubMed: PMID 31272931 · NCT01663402 · Atherosclerosis
  8. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin.
    Otake H, Sugizaki Y, Toba T, et al. · J Cardiol · 2020 · Derived
    PubMed: PMID 30579806 · NCT03552432 (ALTAIR) · Coronary Artery Disease
  9. Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin.
    Müller-Wieland D, Rader DJ, Moriarty PM, et al. · J Clin Endocrinol Metab · 2020 · Derived
    PubMed: PMID 31166599 · NCT01926782 · Hypercholesterolemia
  10. Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.
    Jukema JW, Zijlstra LE, Bhatt DL, et al. · Circulation · 2020 · Derived
    PubMed: PMID 31707788 · NCT01663402 · Atherosclerosis
  11. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.
    Jukema JW, Szarek M, Zijlstra LE, et al. · J Am Coll Cardiol · 2020 · Derived
    PubMed: PMID 30898609 · NCT01663402 · Atherosclerosis
  12. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
    Hopkins PN, Krempf M, Bruckert E, et al. · J Clin Lipidol · 2020 · Derived
    PubMed: PMID 31767518 · NCT01604824 · Hypercholesterolemia
  13. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.
    Goodman SG, Aylward PE, Szarek M, et al. · J Am Coll Cardiol · 2020 · Derived
    PubMed: PMID 31466614 · NCT01663402 · Atherosclerosis
  14. The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device.
    Frias JP, Koren MJ, Loizeau V, et al. · Clin Ther · 2020 · Derived
    PubMed: PMID 31879033 · NCT03415178 · Hypercholesterolemia
  15. Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.
    Dufour R, Hovingh GK, Guyton JR, et al. · J Clin Lipidol · 2020 · Derived
    PubMed: PMID 30591415 · NCT01954394 (ODYSSEY OLE) · Hypercholesterolemia
  16. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM, Leiter LA, Müller-Wieland D, et al. · Cardiovasc Diabetol · 2020 · Derived
    PubMed: PMID 32035487 · NCT02642159 · Dyslipidemias
  17. A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab.
    Chao TH, Hsiao PJ, Liu ME, et al. · J Chin Med Assoc · 2020 · Derived
    PubMed: PMID 30946207 · NCT02289963 · Hypercholesterolemia
  18. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
    Bittner VA, Szarek M, Aylward PE, et al. · J Am Coll Cardiol · 2020 · Derived
    PubMed: PMID 31948641 · NCT01663402 · Atherosclerosis
  19. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
    Bhatt DL, Briggs AH, Reed SD, et al. · J Am Coll Cardiol · 2020 · Derived
    PubMed: PMID 32381160 · NCT01663402 · Atherosclerosis
  20. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome　- The ODYSSEY J-IVUS Trial.
    Ako J, Hibi K, Tsujita K, et al. · Circ J · 2020 · Derived
    PubMed: PMID 31434809 · NCT02984982 (ODYSSEY J-IVUS) · Hypercholesterolemia
  21. Biology, pathophysiology and current therapies that affect lipoprotein (a) levels.
    Rawther T, Tabet F · J Mol Cell Cardiol · 2020 · Background
    PubMed: PMID 30986377 · NCT04613167 (GEBI) · Dyslipidemias
  22. Early detection of cardiac allograft vasculopathy using highly automated 3-dimensional optical coherence tomography analysis.
    Pazdernik M, Chen Z, Bedanova H, et al. · J Heart Lung Transplant · 2020 · Background
    PubMed: PMID 29706574 · NCT04193306 (ACAV)
  23. Magnetic Resonance Imaging Detection of Intraplaque Hemorrhage.
    McNally JS, Kim SE, Mendes J, et al. · Magn Reson Insights · 2020 · Background
    PubMed: PMID 28469441 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  24. Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration.
    Ma L, Chan DC, Ooi EMM, et al. · Metabolism · 2020 · Background
    PubMed: PMID 30995439 · NCT04613167 (GEBI) · Dyslipidemias
  25. Is the future of symptomatic intracranial atherosclerotic stenosis management promising?
    Liu D, Liu J, Cai Y, et al. · J Neurol Neurosurg Psychiatry · 2020 · Background
    PubMed: PMID 31919104 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  26. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
    Koskinas KC, Windecker S, Pedrazzini G, et al. · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 31479722 · NCT06083961 · Ischemic Stroke
  27. Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
    Kim D, Park JM, Kang K, et al. · Stroke · 2020 · Background
    PubMed: PMID 30932785 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  28. Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study.
    Hurford R, Wolters FJ, Li L, et al. · Lancet Neurol · 2020 · Background
    PubMed: PMID 32333899 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  29. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Grundy SM, Stone NJ, Bailey AL, et al. · Circulation · 2020 · Background
    PubMed: PMID 30586774 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  30. Intensive Statin Treatment in Acute Ischaemic Stroke Patients with Intracranial Atherosclerosis: a High-Resolution Magnetic Resonance Imaging study (STAMINA-MRI Study).
    Chung JW, Cha J, Lee MJ, et al. · J Neurol Neurosurg Psychiatry · 2020 · Background
    PubMed: PMID 31371644 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis

2019 (10 papers)

  1. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.
    Leiter LA, Tinahones FJ, Karalis DG, et al. · Diabet Med · 2019 · Derived
    PubMed: PMID 30183102 · NCT01730053 · Hypercholesterolemia
  2. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT).
    Koh KK, Nam CW, Chao TH, et al. · J Clin Lipidol · 2019 · Derived
    PubMed: PMID 29153823 · NCT02289963 · Hypercholesterolemia
  3. Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia.
    Hovingh GK, Guyton JR, Langslet G, et al. · J Clin Lipidol · 2019 · Derived
    PubMed: PMID 30287210 · NCT01954394 (ODYSSEY OLE) · Hypercholesterolemia
  4. Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.
    Farnier M, Hovingh GK, Langslet G, et al. · Atherosclerosis · 2019 · Derived
    PubMed: PMID 30293878 · NCT01954394 (ODYSSEY OLE) · Hypercholesterolemia
  5. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.
    Ako J, Hibi K, Kozuma K, et al. · J Cardiol · 2019 · Derived
    PubMed: PMID 29606415 · NCT02984982 (ODYSSEY J-IVUS) · Hypercholesterolemia
  6. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease.
    Tada H, Takamura M, Kawashiri MA, et al. · J Atheroscler Thromb · 2019 · Background
    PubMed: PMID 31061262 · NCT04613167 (GEBI) · Dyslipidemias
  7. Effect of Evolocumab on Coronary Plaque Composition.
    Nicholls SJ, Puri R, Anderson T, et al. · J Am Coll Cardiol · 2019 · Background
    PubMed: PMID 30336824 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  8. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
    Julius U, Tselmin S, Schatz U, et al. · Clin Res Cardiol Suppl · 2019 · Background
    PubMed: PMID 30838555 · NCT04613167 (GEBI) · Dyslipidemias
  9. Evolocumab and clinical outcomes in patients with cardiovascular disease.
    Hadjiphilippou S, Ray KK · J R Coll Physicians Edinb · 2019 · Background
    PubMed: PMID 28675189 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  10. Quantitative 3D Analysis of Coronary Wall Morphology in Heart Transplant Patients: OCT-Assessed Cardiac Allograft Vasculopathy Progression.
    Chen Z, Pazdernik M, Zhang H, et al. · Med Image Anal · 2019 · Background
    PubMed: PMID 30253306 · NCT04193306 (ACAV)

2018 (16 papers)

  1. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
    Stroes E, Guyton JR, Lepor N, et al. · J Am Heart Assoc · 2018 · Trial result
    PubMed: PMID 27625344 · NCT02023879 · Hypercholesterolemia
  2. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J, Poitiers F, Paehler T, et al. · J Am Heart Assoc · 2018 · Trial result
    PubMed: PMID 27287699 · NCT01723735 · Hypercholesterolemia
  3. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
    Schwartz GG, Steg PG, Szarek M, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 30403574 · NCT01663402 · Atherosclerosis
  4. Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.
    Ray KK, Leiter LA, Müller-Wieland D, et al. · Diabetes Obes Metab · 2018 · Derived
    PubMed: PMID 29436756 · NCT02642159 · Dyslipidemias
  5. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D, Leiter LA, Cariou B, et al. · Cardiovasc Diabetol · 2018 · Derived
    PubMed: PMID 28545518 · NCT02642159 · Dyslipidemias
  6. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.
    Leiter LA, Cariou B, Müller-Wieland D, et al. · Diabetes Obes Metab · 2018 · Derived
    PubMed: PMID 28905478 · NCT02585778 · Hypercholesterolemia
  7. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.
    Defesche JC, Stefanutti C, Langslet G, et al. · J Clin Lipidol · 2018 · Derived
    PubMed: PMID 28964736 · NCT01709513 · Hypercholesterolemia
  8. Effect of recurrent stroke on poor functional outcome in transient ischemic attack or minor stroke.
    Wang A, Wu L, Wang X, et al. · Int J Stroke · 2018 · Background
    PubMed: PMID 27012273 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  9. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T, Kondo A, Kiyosue A, et al. · Lipids Health Dis · 2018 · Background
    PubMed: PMID 28623954 · NCT02584504 (ODYSSEY-NIPPON) · Hypercholesterolemia
  10. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.
    Moriarty PM, Parhofer KG, Babirak SP, et al. · Eur Heart J · 2018 · Background
    PubMed: PMID 27572070 · NCT02326220 (ODYSSEY ESCAPE)
  11. Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.
    Karatasakis A, Danek BA, Karacsonyi J, et al. · J Am Heart Assoc · 2018 · Background
    PubMed: PMID 29223954 · NCT03634293 · Sepsis
  12. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    Johnston SC, Easton JD, Farrant M, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29766750 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  13. Gadolinium Enhancement in Intracranial Atherosclerotic Plaque and Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Gupta A, Baradaran H, Al-Dasuqi K, et al. · J Am Heart Assoc · 2018 · Background
    PubMed: PMID 27528408 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  14. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.
    Choi J, Khan AM, Jarmin M, et al. · Lipids Health Dis · 2018 · Background
    PubMed: PMID 28738813 · NCT03634293 · Sepsis
  15. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.
    Brilakis ES, Edson R, Bhatt DL, et al. · Lancet · 2018 · Background
    PubMed: PMID 29759512 · NCT03542110 (ASAP-SVG)
  16. Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.
    Berger JM, Loza Valdes A, Gromada J, et al. · J Lipid Res · 2018 · Background
    PubMed: PMID 28600283 · NCT03634293 · Sepsis

2017 (19 papers)

  1. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies).
    Teramoto T, Kobayashi M, Uno K, et al. · Am J Cardiol · 2017 · Trial result
    PubMed: PMID 27184170 · NCT01448317 · Hypercholesterolemia
  2. Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　- ODYSSEY JAPAN Randomized Controlled Trial.
    Teramoto T, Kobayashi M, Tasaki H, et al. · Circ J · 2017 · Trial result
    PubMed: PMID 27452202 · NCT02107898 · Hypercholesterolemia
  3. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.
    Reyes-Soffer G, Pavlyha M, Ngai C, et al. · Circulation · 2017 · Trial result
    PubMed: PMID 27986651 · NCT01959971 · Hypercholesterolemia
  4. Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis.
    Krane V, Schmidt KR, Gutjahr-Lengsfeld LJ, et al. · Kidney Int · 2017 · Trial result
    PubMed: PMID 26924051 · NCT03480568 · Hypercholesterolemia
  5. Intracoronary imaging of coronary atherosclerosis: validation for diagnosis, prognosis and treatment.
    Koskinas KC, Ughi GJ, Windecker S, et al. · Eur Heart J · 2017 · Trial result
    PubMed: PMID 26655874 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  6. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN, Rader DJ, Raal FJ, et al. · Cardiovasc Drugs Ther · 2017 · Trial result
    PubMed: PMID 27618825 · NCT01617655 · Hypercholesterolemia
  7. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.
    Roth EM, Moriarty PM, Bergeron J, et al. · Atherosclerosis · 2017 · Derived
    PubMed: PMID 27639753 · NCT01926782 · Hypercholesterolemia
  8. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
    Ray KK, Ginsberg HN, Davidson MH, et al. · Circulation · 2017 · Derived
    PubMed: PMID 27777279 · NCT01644188 · Hypercholesterolemia
  9. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.
    Moriarty PM, Parhofer KG, Babirak SP, et al. · J Clin Lipidol · 2017 · Derived
    PubMed: PMID 27206951 · NCT02326220 (ODYSSEY ESCAPE)
  10. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ, Hovingh GK, Langslet G, et al. · J Clin Lipidol · 2017 · Derived
    PubMed: PMID 28391886 · NCT01709500 (ODYSSEY FH II)
  11. Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment.
    Dufour R, Bergeron J, Gaudet D, et al. · Int J Cardiol · 2017 · Derived
    PubMed: PMID 27886619 · NCT01576484 · Hypercholesterolemia
  12. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.
    Tsimikas S · J Am Coll Cardiol · 2017 · Background
    PubMed: PMID 28183512 · NCT04613167 (GEBI) · Dyslipidemias
  13. An assessment on the incremental value of high-resolution magnetic resonance imaging to identify culprit plaques in atherosclerotic disease of the middle cerebral artery.
    Teng Z, Peng W, Zhan Q, et al. · Eur Radiol · 2017 · Background
    PubMed: PMID 26376883 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  14. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
    Sabatine MS, Giugliano RP, Keech AC, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28304224 · NCT06083961 · Ischemic Stroke
  15. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.
    Norata GD, Tavori H, Pirillo A, et al. · Cardiovasc Res · 2017 · Background
    PubMed: PMID 27496869 · NCT03634293 · Sepsis
  16. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ, Puri R, Anderson T, et al. · JAMA · 2017 · Background
    PubMed: PMID 27846344 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  17. Intracranial Vessel Wall MRI: Principles and Expert Consensus Recommendations of the American Society of Neuroradiology.
    Mandell DM, Mossa-Basha M, Qiao Y, et al. · AJNR Am J Neuroradiol · 2017 · Background
    PubMed: PMID 27469212 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  18. Intracranial plaque enhancement from high resolution vessel wall magnetic resonance imaging predicts stroke recurrence.
    Kim JM, Jung KH, Sohn CH, et al. · Int J Stroke · 2017 · Background
    PubMed: PMID 26783308 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  19. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
    Gouni-Berthold I, Descamps OS, Fraass U, et al. · Br J Clin Pharmacol · 2017 · Background
    PubMed: PMID 27478094 · NCT03634293 · Sepsis

2016 (17 papers)

  1. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
    Moriarty PM, Thompson PD, Cannon CP, et al. · J Clin Lipidol · 2016 · Trial result
    PubMed: PMID 26687696 · NCT01709513 · Hypercholesterolemia
  2. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
    Kastelein JJ, Ginsberg HN, Langslet G, et al. · Eur Heart J · 2016 · Trial result
    PubMed: PMID 26330422 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  3. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
    Cannon CP, Cariou B, Blom D, et al. · Eur Heart J · 2016 · Trial result
    PubMed: PMID 25687353 · NCT01644188 · Hypercholesterolemia
  4. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo.
    Toth PP, Hamon SC, Jones SR, et al. · Lipids Health Dis · 2016 · Derived
    PubMed: PMID 26872608 · NCT01266876 · Hypercholesterolemia
  5. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
    Koren MJ, Kereiakes D, Pourfarzib R, et al. · J Am Heart Assoc · 2016 · Derived
    PubMed: PMID 26586732 · NCT01288443 · Hypercholesterolemia
  6. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.
    Hopkins PN, Defesche J, Fouchier SW, et al. · Circ Cardiovasc Genet · 2016 · Derived
    PubMed: PMID 26374825 · NCT01604824 · Hypercholesterolemia
  7. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M, Jones P, Severance R, et al. · Atherosclerosis · 2016 · Derived
    PubMed: PMID 26638010 · NCT01730053 · Hypercholesterolemia
  8. The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance.
    Walley KR, Francis GA, Opal SM, et al. · Am J Respir Crit Care Med · 2016 · Background
    PubMed: PMID 26252194 · NCT03634293 · Sepsis
  9. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
    Singer M, Deutschman CS, Seymour CW, et al. · JAMA · 2016 · Background
    PubMed: PMID 26903338 · NCT03634293 · Sepsis
  10. Carotid MRI Detection of Intraplaque Hemorrhage at 3T and 1.5T.
    Scott McNally J, Yoon HC, Kim SE, et al. · J Neuroimaging · 2016 · Background
    PubMed: PMID 25040677 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  11. Branch Atheromatous Disease: A Clinically Meaningful, Yet Unproven Concept.
    Petrone L, Nannoni S, Del Bene A, et al. · Cerebrovasc Dis · 2016 · Background
    PubMed: PMID 26671513 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  12. Definition of Best Medical Treatment in Asymptomatic and Symptomatic Carotid Artery Stenosis.
    Paraskevas KI, Mikhailidis DP, Veith FJ, et al. · Angiology · 2016 · Background
    PubMed: PMID 26721504 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  13. Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms.
    Oliveira-Paula GH, Lacchini R, Tanus-Santos JE, et al. · Gene · 2016 · Background
    PubMed: PMID 26428312 · NCT04613167 (GEBI) · Dyslipidemias
  14. Lipoprotein (a) measurements for clinical application.
    Marcovina SM, Albers JJ · J Lipid Res · 2016 · Background
    PubMed: PMID 26637278 · NCT04613167 (GEBI) · Dyslipidemias
  15. Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.
    Kotsia AP, Rangan BV, Christopoulos G, et al. · J Invasive Cardiol · 2016 · Background
    PubMed: PMID 26429851 · NCT03542110 (ASAP-SVG)
  16. A pathological perspective on the natural history of cerebral atherosclerosis.
    Gutierrez J, Elkind MS, Virmani R, et al. · Int J Stroke · 2016 · Background
    PubMed: PMID 25854637 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  17. Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis.
    Brott TG, Howard G, Roubin GS, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 26890472 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis

2015 (24 papers)

  1. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.
    Roth EM, Taskinen MR, Ginsberg HN, et al. · Int J Cardiol · 2015 · Trial result
    PubMed: PMID 25037695 · NCT01644474 (ODYSSEY MONO) · Hypercholesterolemia
  2. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks.
    Roth EM, McKenney JM · Future Cardiol · 2015 · Trial result
    PubMed: PMID 25606700 · NCT01644474 (ODYSSEY MONO) · Hypercholesterolemia
  3. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG, Farnier M, Krempf M, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 25773378 · NCT01507831 · Hypercholesterolemia
  4. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.
    Räber L, Taniwaki M, Zaugg S, et al. · Eur Heart J · 2015 · Trial result
    PubMed: PMID 25182248 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  5. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Kereiakes DJ, Robinson JG, Cannon CP, et al. · Am Heart J · 2015 · Trial result
    PubMed: PMID 26027630 · NCT01644175 · Hypercholesterolemia
  6. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    Everett BM, Smith RJ, Hiatt WR, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 26444323 · NCT03480568 · Hypercholesterolemia
  7. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
    Schwartz GG, Bessac L, Berdan LG, et al. · Am Heart J · 2015 · Derived
    PubMed: PMID 25440796 · NCT01663402 · Atherosclerosis
  8. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
    Robinson JG, Colhoun HM, Bays HE, et al. · Clin Cardiol · 2015 · Derived
    PubMed: PMID 25269777 · NCT01730040 · Hypercholesterolemia
  9. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects.
    Lunven C, Paehler T, Poitiers F, et al. · Cardiovasc Ther · 2015 · Derived
    PubMed: PMID 25256660 · NCT01785329 · Hypercholesterolemia
  10. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
    Kastelein JJ, Robinson JG, Farnier M, et al. · Cardiovasc Drugs Ther · 2015 · Derived
    PubMed: PMID 24842558 · NCT01709500 (ODYSSEY FH II)
  11. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
    Bays H, Gaudet D, Weiss R, et al. · J Clin Endocrinol Metab · 2015 · Derived
    PubMed: PMID 26030325 · NCT01730040 · Hypercholesterolemia
  12. Recurrent stroke was associated with poor quality of life in patients with transient ischemic attack or minor stroke: finding from the CHANCE trial.
    Wang YL, Pan YS, Zhao XQ, et al. · CNS Neurosci Ther · 2015 · Background
    PubMed: PMID 25307297 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  13. PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
    Walley KR, Thain KR, Russell JA, et al. · Sci Transl Med · 2015 · Background
    PubMed: PMID 25320235 · NCT03634293 · Sepsis
  14. Multicontrast high-resolution vessel wall magnetic resonance imaging and its value in differentiating intracranial vasculopathic processes.
    Mossa-Basha M, Hwang WD, De Havenon A, et al. · Stroke · 2015 · Background
    PubMed: PMID 25953365 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  15. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
    Moriarty PM, Jacobson TA, Bruckert E, et al. · J Clin Lipidol · 2015 · Background
    PubMed: PMID 25499937 · NCT01709513 · Hypercholesterolemia
  16. Lipoprotein (a): structure, pathophysiology and clinical implications.
    Maranhão RC, Carvalho PO, Strunz CC, et al. · Arq Bras Cardiol · 2015 · Background
    PubMed: PMID 25120086 · NCT04613167 (GEBI) · Dyslipidemias
  17. Endothelial nitric oxide synthase genotypes modulate peripheral vasodilatory properties after myocardial infarction.
    Machado-Silva W, Alfinito-Kreis R, Carvalho LS, et al. · Gene · 2015 · Background
    PubMed: PMID 26002446 · NCT04613167 (GEBI) · Dyslipidemias
  18. The Latest Information on Intracranial Atherosclerosis: Diagnosis and Treatment.
    Koo J · Interv Neurol · 2015 · Background
    PubMed: PMID 26600797 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  19. Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.
    Huynh K · Nat Rev Cardiol · 2015 · Background
    PubMed: PMID 25824512 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  20. Bridging lipid metabolism and innate host defense.
    dos Santos C, Marshall JC · Sci Transl Med · 2015 · Background
    PubMed: PMID 25320231 · NCT03634293 · Sepsis
  21. Nonstenotic Culprit Plaque: The Utility of High-Resolution Vessel Wall MRI of Intracranial Vessels after Ischemic Stroke.
    de Havenon A, Yuan C, Tirschwell D, et al. · Case Rep Radiol · 2015 · Background
    PubMed: PMID 26346855 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  22. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
    Colhoun HM, Robinson JG, Farnier M, et al. · BMC Cardiovasc Disord · 2015 · Background
    PubMed: PMID 25240705 · NCT01644188 · Hypercholesterolemia
  23. How recent data have impacted the treatment of internal carotid artery stenosis.
    Chaturvedi S, Sacco RL · J Am Coll Cardiol · 2015 · Background
    PubMed: PMID 25790886 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  24. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial.
    Bonati LH, Dobson J, Featherstone RL, et al. · Lancet · 2015 · Background
    PubMed: PMID 25453443 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis

2014 (16 papers)

  1. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Stone NJ, Robinson JG, Lichtenstein AH, et al. · J Am Coll Cardiol · 2014 · Trial result
    PubMed: PMID 24239923 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  2. Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.
    Shoji T · Clin Exp Nephrol · 2014 · Trial result
    PubMed: PMID 24072417 · NCT03480568 · Hypercholesterolemia
  3. Differential healing response attributed to culprit lesions of patients with acute coronary syndromes and stable coronary artery after implantation of drug-eluting stents: an optical coherence tomography study.
    Räber L, Zanchin T, Baumgartner S, et al. · Int J Cardiol · 2014 · Trial result
    PubMed: PMID 24631113 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  4. Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction.
    Madder RD, Goldstein JA, Madden SP, et al. · JACC Cardiovasc Interv · 2014 · Trial result
    PubMed: PMID 23871513 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  5. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).
    Gaudet D, Kereiakes DJ, McKenney JM, et al. · Am J Cardiol · 2014 · Trial result
    PubMed: PMID 25060413 · NCT01288443 · Hypercholesterolemia
  6. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis.
    Windecker S, Stortecky S, Stefanini GG, et al. · BMJ · 2014 · Background
    PubMed: PMID 24958153 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  7. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study.
    Wang Y, Zhao X, Liu L, et al. · Stroke · 2014 · Background
    PubMed: PMID 24481975 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  8. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Stone NJ, Robinson JG, Lichtenstein AH, et al. · Circulation · 2014 · Background
    PubMed: PMID 24222016 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  9. PCSK9: a key modulator of cardiovascular health.
    Seidah NG, Awan Z, Chrétien M, et al. · Circ Res · 2014 · Background
    PubMed: PMID 24625727 · NCT03634293 · Sepsis
  10. Five-year follow-up of the plaque sealing with paclitaxel-eluting stents vs medical therapy for the treatment of intermediate nonobstructive saphenous vein graft lesions (VELETI) trial.
    Rodés-Cabau J, Bertrand OF, Larose E, et al. · Can J Cardiol · 2014 · Background
    PubMed: PMID 24365196 · NCT03542110 (ASAP-SVG)
  11. Gram-positive and gram-negative bacterial toxins in sepsis: a brief review.
    Ramachandran G · Virulence · 2014 · Background
    PubMed: PMID 24193365 · NCT03634293 · Sepsis
  12. Ischemic stroke subtype classification: an asian viewpoint.
    Kim BJ, Kim JS · J Stroke · 2014 · Background
    PubMed: PMID 24741560 · NCT06083961 · Ischemic Stroke
  13. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K, Park BS, Kim YW, et al. · Am J Kidney Dis · 2014 · Background
    PubMed: PMID 24315769 · NCT03004001 · Dyslipidemias
  14. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment.
    Holmstedt CA, Turan TN, Chimowitz MI, et al. · Lancet Neurol · 2014 · Background
    PubMed: PMID 24135208 · NCT06052020 (EAST-sICAS) · Stroke
  15. Saphenous vein graft interventions.
    Brilakis ES, Lee M, Mehilli J, et al. · Curr Treat Options Cardiovasc Med · 2014 · Background
    PubMed: PMID 24643432 · NCT03542110 (ASAP-SVG)
  16. Intracranial atherosclerosis: current understanding and perspectives.
    Bang OY · J Stroke · 2014 · Background
    PubMed: PMID 24741562 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis

2013 (6 papers)

  1. eNOS gene variants and the risk of premature myocardial infarction.
    Zigra AM, Rallidis LS, Anastasiou G, et al. · Dis Markers · 2013 · Background
    PubMed: PMID 23594558 · NCT04613167 (GEBI) · Dyslipidemias
  2. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
    Wang Y, Wang Y, Zhao X, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23803136 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  3. Single subcortical infarction associated with parental arterial disease: important yet neglected sub-type of atherothrombotic stroke.
    Kim JS, Yoon Y · Int J Stroke · 2013 · Background
    PubMed: PMID 22568537 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  4. Carotid plaque hemorrhage on magnetic resonance imaging strongly predicts recurrent ischemia and stroke.
    Hosseini AA, Kandiyil N, Macsweeney ST, et al. · Ann Neurol · 2013 · Background
    PubMed: PMID 23463579 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  5. Carotid plaque MRI and stroke risk: a systematic review and meta-analysis.
    Gupta A, Baradaran H, Schweitzer AD, et al. · Stroke · 2013 · Background
    PubMed: PMID 23988640 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  6. Asymptomatic carotid artery stenosis and the risk of ischemic stroke according to subtype in patients with clinical manifest arterial disease.
    den Hartog AG, Achterberg S, Moll FL, et al. · Stroke · 2013 · Background
    PubMed: PMID 23404720 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis

2012 (10 papers)

  1. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation.
    Tearney GJ, Regar E, Akasaka T, et al. · J Am Coll Cardiol · 2012 · Trial result
    PubMed: PMID 22421299 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  2. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
    Roth EM, McKenney JM, Hanotin C, et al. · N Engl J Med · 2012 · Trial result
    PubMed: PMID 23113833 · NCT01288469 · Hypercholesterolemia
  3. Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients.
    Rogacev KS, Pinsdorf T, Weingärtner O, et al. · Clin J Am Soc Nephrol · 2012 · Trial result
    PubMed: PMID 22461539 · NCT03480568 · Hypercholesterolemia
  4. In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy.
    Pu J, Mintz GS, Brilakis ES, et al. · Eur Heart J · 2012 · Trial result
    PubMed: PMID 22019821 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  5. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM, Koren MJ, Kereiakes DJ, et al. · J Am Coll Cardiol · 2012 · Trial result
    PubMed: PMID 22463922 · NCT01288443 · Hypercholesterolemia
  6. Definitions and methodology for the grayscale and radiofrequency intravascular ultrasound and coronary angiographic analyses.
    Maehara A, Cristea E, Mintz GS, et al. · JACC Cardiovasc Imaging · 2012 · Trial result
    PubMed: PMID 22421222 · NCT03067844 (PACMAN-AMI) · Plaque, Atherosclerotic
  7. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA, Gipe D, Bergeron J, et al. · Lancet · 2012 · Derived
    PubMed: PMID 22633824 · NCT01266876 · Hypercholesterolemia
  8. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits.
    Yamamoto Y, Ohara T, Hamanaka M, et al. · J Neurol Sci · 2012 · Background
    PubMed: PMID 21402390 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  9. Middle cerebral artery intraplaque hemorrhage: prevalence and clinical relevance.
    Xu WH, Li ML, Gao S, et al. · Ann Neurol · 2012 · Background
    PubMed: PMID 22367991 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  10. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials.
    Pursnani S, Korley F, Gopaul R, et al. · Circ Cardiovasc Interv · 2012 · Background
    PubMed: PMID 22872053 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis

2011 (9 papers)

  1. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.
    van der Velde M, Matsushita K, Coresh J, et al. · Kidney Int · 2011 · Trial result
    PubMed: PMID 21307840 · NCT03480568 · Hypercholesterolemia
  2. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
    März W, Genser B, Drechsler C, et al. · Clin J Am Soc Nephrol · 2011 · Trial result
    PubMed: PMID 21493741 · NCT03480568 · Hypercholesterolemia
  3. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
    Baigent C, Landray MJ, Reith C, et al. · Lancet · 2011 · Trial result
    PubMed: PMID 21663949 · NCT03480568 · Hypercholesterolemia
  4. Understanding saphenous vein graft patency.
    Sabik JF · Circulation · 2011 · Background
    PubMed: PMID 21768550 · NCT03542110 (ASAP-SVG)
  5. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
    Launer LJ, Miller ME, Williamson JD, et al. · Lancet Neurol · 2011 · Background
    PubMed: PMID 21958949 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  6. Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design.
    Hong KS, Yegiaian S, Lee M, et al. · Circulation · 2011 · Background
    PubMed: PMID 21536995 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  7. Chinese ischemic stroke subclassification.
    Gao S, Wang YJ, Xu AD, et al. · Front Neurol · 2011 · Background
    PubMed: PMID 21427797 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  8. Stenting versus aggressive medical therapy for intracranial arterial stenosis.
    Chimowitz MI, Lynn MJ, Derdeyn CP, et al. · N Engl J Med · 2011 · Background
    PubMed: PMID 21899409 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  9. Intracranial atherosclerosis: current concepts.
    Arenillas JF · Stroke · 2011 · Background
    PubMed: PMID 21164126 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis

2010 (3 papers)

  1. Excerpts from the US Renal Data System 2009 Annual Data Report.
    Collins AJ, Foley RN, Herzog C, et al. · Am J Kidney Dis · 2010 · Trial result
    PubMed: PMID 20082919 · NCT03480568 · Hypercholesterolemia
  2. Epidemiology of intracranial stenosis.
    Suri MF, Johnston SC · J Neuroimaging · 2010 · Background
    PubMed: PMID 19807851 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  3. Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
    Clarke R, Peden JF, Hopewell JC, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20032323 · NCT04613167 (GEBI) · Dyslipidemias

2009 (7 papers)

  1. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
    Fellström BC, Jardine AG, Schmieder RE, et al. · N Engl J Med · 2009 · Trial result
    PubMed: PMID 19332456 · NCT03480568 · Hypercholesterolemia
  2. On-pump versus off-pump coronary-artery bypass surgery.
    Shroyer AL, Grover FL, Hattler B, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19890125 · NCT03542110 (ASAP-SVG)
  3. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial.
    Rodés-Cabau J, Bertrand OF, Larose E, et al. · Circulation · 2009 · Background
    PubMed: PMID 19884468 · NCT03542110 (ASAP-SVG)
  4. Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q.
    Ober C, Nord AS, Thompson EE, et al. · J Lipid Res · 2009 · Background
    PubMed: PMID 19124843 · NCT04613167 (GEBI) · Dyslipidemias
  5. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.
    Lichtenwalter C, de Lemos JA, Roesle M, et al. · JACC Cardiovasc Interv · 2009 · Background
    PubMed: PMID 19778774 · NCT03542110 (ASAP-SVG)
  6. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
    Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. · JAMA · 2009 · Background
    PubMed: PMID 19622820 · NCT04613167 (GEBI) · Dyslipidemias
  7. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.
    Chasman DI, Shiffman D, Zee RY, et al. · Atherosclerosis · 2009 · Background
    PubMed: PMID 18775538 · NCT04613167 (GEBI) · Dyslipidemias

2008 (3 papers)

  1. Plasma PCSK9 preferentially reduces liver LDL receptors in mice.
    Grefhorst A, McNutt MC, Lagace TA, et al. · J Lipid Res · 2008 · Background
    PubMed: PMID 18354138 · NCT03634293 · Sepsis
  2. Inflammation stimulates the expression of PCSK9.
    Feingold KR, Moser AH, Shigenaga JK, et al. · Biochem Biophys Res Commun · 2008 · Background
    PubMed: PMID 18638454 · NCT03634293 · Sepsis
  3. 2006 National Hospital Discharge Survey.
    DeFrances CJ, Lucas CA, Buie VC, et al. · Natl Health Stat Report · 2008 · Background
    PubMed: PMID 18841653 · NCT03542110 (ASAP-SVG)

2007 (4 papers)

  1. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome.
    Kovesdy CP, Anderson JE, Kalantar-Zadeh K, et al. · J Am Soc Nephrol · 2007 · Trial result
    PubMed: PMID 17167114 · NCT03480568 · Hypercholesterolemia
  2. Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting.
    Rodés-Cabau J, Facta A, Larose E, et al. · Am J Cardiol · 2007 · Background
    PubMed: PMID 17697821 · NCT03542110 (ASAP-SVG)
  3. Molecular biology of PCSK9: its role in LDL metabolism.
    Horton JD, Cohen JC, Hobbs HH, et al. · Trends Biochem Sci · 2007 · Background
    PubMed: PMID 17215125 · NCT03634293 · Sepsis
  4. Anatomic and pathologic spectrum of pituitary infundibulum lesions.
    Hamilton BE, Salzman KL, Osborn AG, et al. · AJR Am J Roentgenol · 2007 · Background
    PubMed: PMID 17312027 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis

2006 (4 papers)

  1. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
    Weinberger J · Curr Cardiol Rep · 2006 · Background
    PubMed: PMID 16507227 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis
  2. Low-grade carotid stenosis: looking beyond the lumen with MRI.
    Wasserman BA, Wityk RJ, Trout HH, et al. · Stroke · 2006 · Background
    PubMed: PMID 16239630 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  3. Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study.
    van Straaten EC, Fazekas F, Rostrup E, et al. · Stroke · 2006 · Background
    PubMed: PMID 16439704 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  4. High-dose atorvastatin after stroke or transient ischemic attack.
    Amarenco P, Bogousslavsky J, Callahan A, et al. · N Engl J Med · 2006 · Background
    PubMed: PMID 16899775 · NCT05001984 (TOPICAL-MRI) · Intracranial Arteriosclerosis

2005 (3 papers)

  1. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C, Krane V, März W, et al. · N Engl J Med · 2005 · Trial result
    PubMed: PMID 16034009 · NCT03480568 · Hypercholesterolemia
  2. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
    Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 15800226 · NCT03507374 (PINNACLE) · Intracranial Arteriosclerosis
  3. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
    Alexander JH, Hafley G, Harrington RA, et al. · JAMA · 2005 · Background
    PubMed: PMID 16287955 · NCT03542110 (ASAP-SVG)

2004 (3 papers)

  1. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study.
    Goldman S, Zadina K, Moritz T, et al. · J Am Coll Cardiol · 2004 · Background
    PubMed: PMID 15582312 · NCT03542110 (ASAP-SVG)
  2. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP, Braunwald E, McCabe CH, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15007110 · NCT06083961 · Ischemic Stroke
  3. Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice.
    Branger J, Knapp S, Weijer S, et al. · Infect Immun · 2004 · Background
    PubMed: PMID 14742522 · NCT03634293 · Sepsis

2003 (1 paper)

  1. Angiographic changes in saphenous vein grafts are predictors of clinical outcomes.
    Knatterud GL, White C, Geller NL, et al. · Am Heart J · 2003 · Background
    PubMed: PMID 12595843 · NCT03542110 (ASAP-SVG)

2001 (1 paper)

  1. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG, Olsson AG, Ezekowitz MD, et al. · JAMA · 2001 · Background
    PubMed: PMID 11277825 · NCT06083961 · Ischemic Stroke

2000 (2 papers)

  1. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome.
    Toto RD, Grundy SM, Vega GL, et al. · Am J Nephrol · 2000 · Background
    PubMed: PMID 10644862 · NCT03004001 · Dyslipidemias
  2. Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.
    Domanski MJ, Borkowf CB, Campeau L, et al. · J Am Coll Cardiol · 2000 · Background
    PubMed: PMID 11092659 · NCT03542110 (ASAP-SVG)

1999 (2 papers)

  1. Gram-positive sepsis. Mechanisms and differences from gram-negative sepsis.
    Sriskandan S, Cohen J · Infect Dis Clin North Am · 1999 · Background
    PubMed: PMID 10340174 · NCT03634293 · Sepsis
  2. A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK.
    Hingorani AD, Liang CF, Fatibene J, et al. · Circulation · 1999 · Background
    PubMed: PMID 10510054 · NCT04613167 (GEBI) · Dyslipidemias

1997 (2 papers)

  1. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.
    Medzhitov R, Preston-Hurlburt P, Janeway CA, et al. · Nature · 1997 · Background
    PubMed: PMID 9237759 · NCT03634293 · Sepsis
  2. Late myocardial ischemic events after saphenous vein graft intervention--importance of initially "nonsignificant" vein graft lesions.
    Ellis SG, Brener SJ, DeLuca S, et al. · Am J Cardiol · 1997 · Background
    PubMed: PMID 9185633 · NCT03542110 (ASAP-SVG)

1996 (3 papers)

  1. Endotoxin suppresses rat hepatic low-density lipoprotein receptor expression.
    Liao W, Rudling M, Angelin B, et al. · Biochem J · 1996 · Background
    PubMed: PMID 8611169 · NCT03634293 · Sepsis
  2. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years.
    Fitzgibbon GM, Kafka HP, Leach AJ, et al. · J Am Coll Cardiol · 1996 · Background
    PubMed: PMID 8772748 · NCT03542110 (ASAP-SVG)
  3. A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM.
    BERG K · Acta Pathol Microbiol Scand · 1996 · Background
    PubMed: PMID 14064818 · NCT04613167 (GEBI) · Dyslipidemias

1995 (1 paper)

  1. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia.
    Vega GL, Toto RD, Grundy SM, et al. · Kidney Int · 1995 · Background
    PubMed: PMID 7723244 · NCT03004001 · Dyslipidemias

1988 (1 paper)

  1. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
    Vega GL, Grundy SM · Kidney Int · 1988 · Background
    PubMed: PMID 3165483 · NCT03004001 · Dyslipidemias

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).